

## Title page

**Title:** An Interim Report of the Scleroderma Clinical Trials Consortium Working Groups

**Short title:** SCTC Working Groups

Murray Baron, MD<sup>1</sup>, Bashar Kahaleh, MD<sup>2</sup>, Elena J. Bernstein, MD, MSc<sup>3</sup>, Lorinda Chung, MD, MS<sup>4</sup>, Philip J. Clements, MD MPH<sup>5</sup>, Christopher Denton, PhD, FRCP<sup>6</sup>, Robyn T. Domsic, MD MPH<sup>7</sup>, Nava Ferdowsi, MD<sup>8</sup>, Ivan Foeldvari, MD<sup>9</sup>, Tracy Frech, M.D., M.S.<sup>10</sup>, Jessica K. Gordon, MSc MD<sup>11</sup>, Marie Hudson, MD<sup>1</sup>, Sindhu R. Johnson, MD PhD<sup>12</sup>, Dinesh Khanna, M.D., M.S.<sup>13</sup>, Zsuzsannah McMahan, M.D., M.H.S.<sup>14</sup>, Peter A. Merkel, MD MPH<sup>15</sup>, Sonali Narain, M.B.B.S., M.P.H.<sup>16</sup>, Mandana Nikpour MBBS FRACP PhD<sup>8</sup>, John D. Pauling, MD PhD<sup>17</sup>, Laura Ross, MD PhD<sup>8</sup>, Antonia Maria Valenzuela Vergara, MD, MS<sup>4</sup>, Alexandra Vacca, M.D.<sup>18</sup>

Affiliations: <sup>1</sup>Division of Rheumatology, Jewish General Hospital, Montreal, Canada, <sup>2</sup>Faculty of Rheumatology, University of Toledo Medical Center, Toledo, OH, USA, <sup>3</sup>Columbia University College of Physicians and Surgeons, New York, New York, <sup>4</sup>Department of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, USA, <sup>5</sup> Ronald Reagan UCLA Medical Center, Los Angeles, CA, USA, <sup>5</sup> University College London, London, United Kingdom, <sup>6</sup>Institute of Immunity and Transplantation, University College London, London, United Kingdom, <sup>7</sup>Arthritis and Autoimmunity Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA, <sup>8</sup>Division of Rheumatology, St. Vincent's Hospital, Melbourne, Australia, <sup>9</sup>Hamburg Centre for Pediatric Rheumatology, Hamburg, Germany, <sup>10</sup>Department of Rheumatology, University of Utah, UT, USA, <sup>11</sup>Department of Rheumatology, Hospital for Special Surgery, New York, NY, USA, <sup>12</sup>Department of Rheumatology, Toronto Western Hospital, Toronto, Canada, <sup>13</sup>Division of Rheumatology, University of Michigan, MI, USA, <sup>14</sup>Rheumatology Department, Johns Hopkins Hospital, M.D., USA, <sup>15</sup>Department of Medicine, University of Pennsylvania, PA, USA, <sup>16</sup>Department of Rheumatology, HofstraNorthwell School of Medicine, <sup>17</sup>Department of Rheumatology, Royal National Hospital for Rheumatic Diseases University of Bath, <sup>18</sup>Faculty of Medicine and Surgery, University of Cagliari, Sardinia, Italy.

Corresponding author:

Murray Baron, MD, Chief Division of Rheumatology. Jewish General Hospital, 3755 Cote St Catherine Rd, A-725, Montreal, QC, H3T 1E2

Tel: 514-340-8231 Fax: 514-340-7906 Email: [mbaron@rhu.jgh.mcgill.ca](mailto:mbaron@rhu.jgh.mcgill.ca)

Word count: 7590

## **Abstract**

The Scleroderma Clinical Trials Consortium (SCTC) represents many of the clinical researchers in the world who are interested in improving the efficiency of clinical trials in Systemic Sclerosis (SSc). The SCTC has established 10 working groups (WGs) to develop and validate better ways of measuring and recording multiple aspects of this heterogeneous disease. These include groups working on arthritis, disease damage, disease activity, cardiac disease, juvenile SSc, the gastrointestinal tract, vascular component, calcinosis, scleroderma renal crisis, interstitial lung disease, and skin measurement. Members of the SCTC may join any one or more of these groups.

Some of the WGs have only recently started their work, some are nearing completion of their mandated tasks and others are in the midst of their projects.

All these projects, which are described in this paper, will help to improve clinical trials and observational studies by improving or developing better, more sensitive ways of measuring various aspects of the disease. As Lord Kelvin stated, “To measure is to know. If you cannot measure it you cannot improve it.” The SCTC is dedicated to improving the lives of patients with SSc and it is our hope that the contributions of the WGs will be one important step in this process.

## **An Interim Report of the Scleroderma Clinical Trials Consortium Working Groups.**

The Scleroderma Clinical Trials Consortium(SCTC) represents the majority of researchers and clinicians in the world who have particular interest and expertise in the care of, and research in, systemic sclerosis (SSc, scleroderma). The mission of the SCTC is to advance knowledge about the treatment of SSc primarily by promoting efficient design, conduct, and reporting of results of clinical trials and observational studies. To this end the SCTC has assembled an assortment of working groups (WGs) that are tasked to investigate various aspects of scleroderma. In general, they are focused on better ways to measure various aspects of the disease. These measures are essential for the conduct of good clinical trials and observational studies.

In this report we will briefly summarize the projects of these WGs.

### **1. Arthritis WG. PI: authors JG,PC and SJ.**

Musculoskeletal disease in SSc leads to disability and poor quality of life<sup>1</sup>. Musculoskeletal disease including arthritis and tendinopathy has been observed in 24% to 97% of SSc patients at some time during the course of their illness<sup>2</sup>. Synovitis, joint contracture, and tendon friction rubs (TFRs) are associated with early disease, disease severity, and with higher degrees of systemic inflammation<sup>3,4</sup>. Joint synovitis and TFRs were shown to be independent predictive factors for disease progression in early SSc<sup>5</sup>. However, these manifestations are frequently overlooked in the context of clinical trials in part because outcome measures have not been developed for Musculoskeletal symptoms<sup>6</sup>. This WG was formed in order to identify a core set of preliminary items considered as important for the study of arthritis and arthropathy in SSc.

In order to explore the opinions of scleroderma experts regarding utility of potential outcome measures in SSc joint disease, we conducted a two-part Delphi exercise. We utilized web-based

technologies to conduct the Delphi exercise. In 2 rounds of electronic voting, experts from the SCTC email list were asked to rate various outcome measures with respect to their use in future clinical trials focused on arthritis in SSc. Individuals ranked each item 1-9 on a Likert scale with the intent to disregard any items with a mean score <3, keep items with a mean score >7 and reconsider items rated between 3 and 7.

Fifty physicians from SCTC centers participated. They were provided with a list of 29 items to consider initially, which was increased to 31 items during the second round. Consensus was achieved after 2 rounds of voting. The experts agreed that the following 7 items should be useful in an arthritis-focused SSc trial: 28 joint tenderness count, 28 joint swelling count, assessment of TFRs, assessment of contractures of small and large joints, C-reactive protein, Scleroderma Health Assessment Questionnaire-Disability Index, patient global visual analogue scale. No items on the list were ranked in the disregard category.

The two round Delphi exercise identified 7 items considered by experts as well-suited for the study of arthritis in SSc, but there was considerable ambivalence regarding the performance of these potential outcome measures for SSc arthritis. The validation of these outcome measures for use in interventional studies of SSc-arthritis is called for and is the focus of this group moving forward.

## **2. Disease Damage WG. PI: authors NF, MB, MN**

The Scleroderma (SSc) Clinical Trials Consortium Damage Index (SCTC-DI) Working Group was assembled in November 2013. The mandate of this working group of 24 members, including 22 rheumatologists and 2 dermatologists from North and South America, Australia and Europe, was to develop the first disease Damage Index in SSc, an instrument to quantify organ damage in this disease. The SCTC-DI Working Group was aided by an Advisory Group of 7 non-

rheumatology experts from the disciplines of cardiology, respiratory medicine, gastroenterology and nephrology, together with 3 patient partners.

The first task of the SCTC-DI Working Group was to achieve a consensus definition of ‘damage’ in SSc. This was achieved through a two-round survey of the Working Group members, and consultation with the Advisory Group and patient partners. Items for potential inclusion were generated through a systematic review of the literature <sup>7</sup> and items were added based on suggestions of the WG members, the Advisory Group and the patient partners. The final list of items was then presented in survey form to the members of the SCTC, who were asked to rate the appropriateness of each item, in terms of importance and feasibility, for inclusion in the SCTC-DI. In this manner, over 80 items were reduced to just over 50. Further item reduction and ‘weighting’ was achieved through regression methods relating each item with the endpoints of quality of life (‘morbidity’) measured using SF-36 and mortality, in the Australian Scleroderma Cohort Study data set of over 1500 patients followed prospectively over a median follow-up of 4 years. External validation of the SCTC-DI in the Canadian Scleroderma Research Group cohort has shown excellent performance characteristics against similar morbidity and mortality endpoints, and steady accrual of damage over time, indicating responsiveness in an observational cohort setting. A manuscript reporting the derivation and initial validation of the SCTC-DI is currently being prepared for submission for peer review publication.

Future projects include prospective validation of the SCTC-DI in the International Systemic Sclerosis Inception Cohort (INSYNC) of patients followed from disease onset, and assessment of discriminant validity in interventional studies. Future applications of the newly derived SCTC-DI include use as an outcome measure and enrichment tool for patient selection in clinical trials, a

tool to describe the course of the disease in observational studies, and an instrument to quantify disease burden for epidemiological studies and policy making.

As activity and damage lie on the same continuum, the development of the SCTC-DI has laid the foundations for the development of an Activity Index using similar methodology.

### **3. Disease Activity WG.** PI: authors LR, MB, MN

The EUSTAR Activity Index (EScSG-AI)<sup>8,9</sup> is the only previously published SSc activity index. This activity index that was recently revised in 2017<sup>9</sup>, has not yet been fully validated. This remains an issue of great clinical significance as SSc continues to have the highest case-based mortality of any autoimmune connective tissue disease<sup>10</sup>. Thus, accurate identification of high disease activity is of utmost importance in order to apply targeted therapy to lower the risk of organ damage.

The SCTC ActivityWG is a collaboration of international SSc experts working towards generating a weighted, multi-system index to identify and measure SSc disease activity. A multidisciplinary advisory panel of non-rheumatology experts from various disciplines, including cardiology, respiratory medicine, gastroenterology and nephrology, and patient partners, has been assembled to provide advice and recommendations regarding aspects of disease activity relevant to their specific fields of expertise.

As a first step in developing an activity index, the SCTC Activity WG developed a consensus, conceptual definition of disease activity in SSc. This conceptual definition of disease activity will then form the central construct of the planned SCTC Activity Index (SCTC-AI). Careful attention will be paid to the Outcome Measures in Rheumatology (OMERACT) filters of truth, discrimination and feasibility<sup>11</sup> in the development of the SCTC-AI.

Using a similar methodology to that employed in the development of SCTC Damage Index (SCTC-DI) (under peer review), development of items for the SCTC-AI will draw upon the expertise of the SCTC WG and systemic review of the literature. Reduction and weighting of items will be performed using data from the Australian Scleroderma Cohort Study (ASCS). Data from the Canadian Scleroderma Research Group (CSRG) cohort study will be used for retrospective validation in an external cohort. Prospective validation of the SCTC-AI will be performed in the International Systemic Sclerosis Inception Cohort (INSYNC), the largest prospective cohort of incident cases of SSc, in order to test the performance of the SCTC-AI in patients with recent-onset disease. In all of these validation studies, the endpoints of interest will be health-related quality of life (HRQoL), physical function, organ damage (measured by the SCTC-DI), and mortality.

By ensuring that the SCTC-AI has face value, measures what is intended, and readily discriminates between high and low disease activity states, it is hoped that the SCTC-AI will overcome the criticisms faced by other outcome measures and be the first fully validated SSc disease activity outcome measure.

#### 4. **Cardiac WGPI:** authors AV,LR, MB, MN

The aim of the SCTC Cardiac WG is to develop a definition of primary cardiac involvement in SSc for use in clinical trials and in observational studies. Currently, there is no consensus definition of SSc-cardiomyopathy and this is reflected in the highly variable reporting of SSc cardiac disease (SCD) and its prevalence. SCD is highly heterogeneous and includes variable involvement of many cardiac structures including the myocardium, conduction system, pericardium and cardiac valves. Early definitions of SCD have included congestive cardiac failure, arrhythmias requiring therapy and symptomatic Pericarditis<sup>12,13</sup>. The prevalence of SCD



using these criteria was 15% in a cohort of patients with diffuse SSc and these patients, particularly those with symptomatic cardiomyopathy, had poor clinical outcomes<sup>13</sup>.

Autopsy studies have demonstrated SCD in up to 80% of patients and whilst no individual finding is pathognomonic for SCD, features of microvascular damage, myocardial fibrosis and inflammation are considered characteristic of SSc heart disease<sup>14,15</sup>. A definition of SCD would ideally incorporate the underlying pathophysiological processes, however routine investigations such as electrocardiography, chest radiograph and transthoracic echocardiography are known to have a low sensitivity for the detection of SCD prior to the onset of clinically overt disease<sup>16</sup>. There is emerging evidence of a role for more sensitive diagnostic techniques such as tissue Doppler echocardiography (TDE), and cardiac magnetic resonance imaging (CMR)<sup>17</sup>, and for biomarkers such as N-terminal pro B-type natriuretic peptide<sup>18</sup>, and high sensitivity cardiac troponin<sup>19,20</sup>. However, the clinical significance of abnormalities detected by newer investigation modalities remains uncertain.

There are a significant number of other unresolved issues when considering SCD; namely, the effect of co-morbidities on the myocardium and attribution of cardiac disease to SSc, as well as appropriate screening algorithms and optimal treatment and follow-up of patients diagnosed with SCD. The lack of an accepted, standardised definition of SCD impedes progress in all of these areas.

The SCTC CardiacWG has recruited cardiologists from Europe, North America and Australia to assist in the development of a preliminary working definition of SCD. The WG will be asked to consider the scope of cardiac disease that should be included in a definition of SCD. Questions to be considered are should the definition of SCD be restricted to SSc affecting the myocardium only, and should SCD considered present only if patients are symptomatic? A scoping literature

review of previously published definitions of SCD has been performed. With these results and by drawing upon the expertise within the group, the Cardiac WG is aiming to develop a consensus, expert-opinion definition of SCD. In parallel, the Cardiac WG is also developing a research agenda to pursue the role of novel echocardiography techniques and CMR in the diagnosis of SCD and establishing cohort studies to better describe the natural history of SSc cardiac disease.

#### **5. Juvenile scleroderma WG. PI: Author IF**

Juvenile systemic scleroderma (jSSc) is a much rarer than the adult form. The estimated prevalence is 3 per 1 million child based on the Administrative Claims Data from the United States (Beukelman and Foeldvari et al, in press JSRD). The only published cross sectional study regarding incidence from the United Kingdom and Ireland that relied upon surveys of specialist, estimated a yearly incidence of 0.27 [0.10-0.50] per 1 million child<sup>21</sup>.

Currently there is a proposed severity index published for jSSc<sup>22</sup>, which is a modification of the Medsger severity index, however it is not yet validated. In the evaluation of the juvenile severity index<sup>22</sup> in the juvenile scleroderma inception cohort population ([www.juvenile-scleroderma.com](http://www.juvenile-scleroderma.com)), the index appears to be unresponsive to improvement but it did correlate with the Modified Rodnan skin score (unpublished data Foeldvari et al).

Several outcome measures exist for adult SSc patients including the Valentini activity index<sup>9</sup>, the CRISS response index<sup>23</sup>, the Medsger severity index<sup>24</sup> and the proposed SCTC damage index. Unfortunately, none is validated in the pediatric population.

As new therapeutics are investigated in adults with SSc, pediatric studies will be planned. It is crucial to define response index, activity index and remission in the pediatric population. A

further important step for jSSc treatment studies is the decision of European Medical Agency on extrapolation of the data<sup>25,26</sup>, to license treatment faster for pediatric orphan diseases.

The aim of the WG is to develop, adopt and validate outcome measures for jSSc.

Three workshops took place during the annual meeting of the “Hamburg Symposium on Juvenile Scleroderma- Update on New Developments”, ([www.juvenile-scleroderma.com](http://www.juvenile-scleroderma.com)) that were organised by Ivan Foeldvari, to develop a pediatric “CRIS” and other pediatric jSSc specific outcome measures. In the last workshop a preliminary pediatric CRIS was proposed (manuscript in preparation). We are also in the process of validating the proposed pediatric and adult parameters in the juvenile scleroderma inception cohort ([www.juvenile-scleroderma.com](http://www.juvenile-scleroderma.com)), and in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) cohort.

We hope that we will have a validated instrument, regarding definition of activity, response, remission and damage, which can be applied in Phase II and III studies testing new therapy for jSSc. The indices will help clinicians in the day to day practice too.

#### **6. Gastrointestinal Tract WG PI: authors TF, ZM, DK**

Gastrointestinal (GI) tract symptoms are very common in SSc. The etiology of these symptoms is thought to be similar to other organ system pathophysiology with interrelated progressive immune dysregulation, vasculopathy, and fibrosis occurring throughout the GI tract. The study of GI symptoms in SSc must capture not only the severity of involvement, but also response of those symptoms to intervention. The ideal patient reported outcome measure should be able to provide information to guide the treating physician and inform clinical trial design while also minimizing the burden on the patient. The SCTC-GI-WG acknowledges the unmet need of a longitudinal assessment of response to therapy in SSc-associated GI tract involvement<sup>27</sup>. Patient

reported outcomes measurement system (PROMIS) questionnaires were developed to characterize GI symptoms from the esophagus to the anorectum. The GI-WG focused on assessing psychometric properties of various GI-specific patient reported outcome measures in 5 conditions—gastroesophageal reflux disease, gastroparesis, small intestinal bowel bacterial overgrowth, constipation, and fecal incontinence. Our WG comprises six international scleroderma centers from the United States and one each from Italy, Belgium and Australia. All data is entered at baseline and in follow-up into a database which was developed and is maintained at the University of Michigan.

We recently assessed the reliability, validity, and sensitivity to change of 3 PROs- the NIH PROMIS-GI Symptoms scale, the Scleroderma Clinical Trials Consortium University of California Los Angeles Gastrointestinal Tract (SCTC UCLA GIT 2.0), and the Quality of life in Reflux and Dyspepsia <sup>28</sup>, in 116 participants with SSc and active GERD with an average age of 53.8 years and mean disease duration of 12.0 years. The UCLA GIT 2.0 Reflux scale and PROMIS Reflux scale had a significant correlation at baseline (0.61,  $p < 0.0001$ ), and both instruments correlated with the QOLRAD domains (-0.56 to -0.71). Both UCLA GIT 2.0 and PROMIS Reflux scales were sensitive to change over time in patients who improved over a period of 4 weeks after an intervention.

The SCTC GI WG is now actively recruiting patients for the other SScGI symptom domains. The next anticipated step is to better clarify the etiology of bloating and distention in an international cohort. Patient reported outcomes instruments that are applied to this cohort after a single intervention for GI symptoms can help inform clinical practice and trial design.

**7. Vascular WG.** PI: authors JP, RD

The aims of the SCTC Vascular WG (VWG) are to develop/improve outcome measures for SSc vascular manifestations. Challenges in establishing treatment efficacy in clinical trials of Raynaud's phenomenon (RP) led the nascent SCTC-VWG to appraise existing methods for assessing SSc-RP. The Raynaud's Condition Score (RCS) is the preferred outcome measure for SSc-RP and is included in the provisional core set of outcome measures for SSc clinical trials<sup>29</sup>. The RCS diary collects information on the frequency, duration and severity/impact of RP in SSc<sup>30</sup>. It is a clinician-derived patient-reported outcome [PRO] instrument, but there was no patient involvement in its development<sup>31</sup>. Therefore, studies have identified poor agreement between the RCS diary and objective methods for assessing digital microvascular function<sup>32,33</sup>. Concerns have also been raised about the magnitude of the placebo effect in clinical trials incorporating the RCS diary<sup>34</sup>.

The SCTC-VWG undertook a survey of the attitudes of SSc experts towards the RCS diary. The SURPASS (Subjective Raynaud's phenomenon Assessment in Systemic Sclerosis) survey identified several concerns about the 2-week RCS diary including the respondent burden and an inability to control for factors that might influence the reporting of RP symptoms<sup>35</sup>.

To this end, SCTC funding was obtained to devise a conceptual framework for a novel patient-derived PRO instrument for SSc-RP, supported by a steering committee comprising SSc patients, SSc experts and qualitative researchers.

Preliminary work included a comprehensive literature review that has highlighted the significant burden associated with SSc-RP not captured by the RCS diary<sup>36</sup>. A multicenter qualitative research study designed to examine the patient experience of SSc-RP from a broad ethnic, geographic and cultural population of SSc patients has supported and expanded these findings<sup>37</sup>. A purposive sampling framework ensured the enrollment of a diverse but representative group of

40 patients with SSc. We identified important experiences of SSc-RP not captured by the RCS diary including emotional distress, body image dissatisfaction, impaired social participation and relevant physical symptoms such as feeling “cold”<sup>37</sup>. Our findings have challenged the prevailing paradigm of SSc-RP being only an episodic phenomenon with physical symptoms such as pain, numbness and loss of hand function reported in a more sustained manner and reflecting persistent digital ischemia in SSc<sup>37</sup>. The considerable efforts taken by patients to avoid or ameliorate SSc-RP attacks were a major theme of the focus groups<sup>37</sup>. In parallel work, SSc patients attending UK and US sites undertook 2-week RCS diary collection and then completed a qualitative survey examining patient attitudes towards the instrument<sup>38</sup>. The findings confirmed our suspicions that the RCS diary underestimates the true burden of RP symptoms and provides insight as to why the RCS diary has not performed as well as hoped in clinical trials whose primary endpoint is the frequency of SSc-RP attacks<sup>38-40</sup>.

Work within the SCTC-VWG is currently underway on item-generation for a novel PRO instrument for SSc-RP, grounded in the patient experience of SSc-RP identified in our preliminary work.

#### **8. Calcinosis WG PI: author LC, AV**

Calcinosis cutis, the deposition of calcium in the skin and subcutaneous tissues, is a common and potentially debilitating issue affecting approximately one quarter of SSc patients<sup>41,42</sup>. To date, there are no effective therapies for this complication and there is a lack of validated outcome measures to use in clinical trials<sup>43</sup>. The SCTC Calcinosis-WG is an international collaborative effort to create new trial outcome measures and better understand the course and consequences of this complication.

Studies have shown an association between calcinosis and vascular manifestations of

SSc including digital ulcers (DUs,<sup>44-46</sup> and acro-osteolysis<sup>47</sup>, suggesting a role for ischemia in the pathogenesis of calcinosis. In addition, microtrauma has been implicated in the pathogenesis of calcinosis, and a prior single-center study found that the thumbs were most commonly affected, supporting this hypothesis<sup>48</sup>.

Our group performed a retrospective analysis involving 5218 patients with SSc from 9 cohorts within the US, Australia, Canada, United Kingdom, Italy, and Mexico. In multivariate analysis, the strongest associations with calcinosis were DUs and osteoporosis<sup>42</sup>.

Our group has developed a novel radiographic scoring system to assess the severity of calcinosis affecting the hands that accounts for area coverage, density, and anatomic location. This scoring system was found to have excellent intra- and inter-rater reliability with intra-class correlation coefficients (ICC) of .93 (.89-.97) and .89 (.86-.92), respectively<sup>49</sup>. Similarly, we have developed a patient reported outcome measure specific to calcinosis (the Mawdsley Calcinosis Questionnaire,<sup>50</sup>

We have established a prospective multi-center cohort of SSc patients with and without calcinosis to better define the natural history, confirm clinical associations, and further validate these novel outcome measures. Data is being collected from 15 centers, 8 of whom are also participating in a sub-study to validate the radiographic scoring system.

We are collecting patient questionnaires at baseline and 1-year, including the Cochin Hand Functional Scale, Scleroderma Health Assessment Questionnaire, patient global assessment of calcinosis using a visual analog scale (VAS, 0-10), and the novel Mawdsley calcinosis questionnaire. In addition, physician global assessment of calcinosis VAS is being collected at baseline and 1-year, and a 5-point Likert scale at the 1-year visit for both patients and physicians to rate change in calcinosis.

Information on 556 patients has been entered into the central database from which 134 have completed 1-year follow-up and 60 are participating in the radiographic sub-study. Enrollment is expected to be completed in March 2018. We plan to compare patients with and without calcinosis with respect to demographic characteristics, clinical features, and autoantibodies, and to specifically assess the association between calcinosis and DU or osteoporosis, adjusting for other relevant variables. We will also determine the mean rate of change of calcinosis for the subset of patients who have baseline and 1-year hand radiographs<sup>49</sup>. We hope to identify a subgroup of patients with rapid calcinosis progression and to determine risk factors for this severe phenotype.

#### **9. Scleroderma Renal Crisis WG.** PI: authors MH,CD

Scleroderma Renal Crisis (SRC) is characterized by acute, malignant hypertension and renal dysfunction. It is a rare complication of SSc, affecting approximately 5% of subjects. The clinical spectrum of SRC is broad, ranging from new onset accelerated arterial hypertension and rapidly progressive oliguric renal failure, to more modest elevations in blood pressure and renal dysfunction, and at times normotensive presentations. To date, two sets of criteria for SRC have been proposed and partially validated<sup>51,52</sup>. We wish to build on these preliminary efforts to develop classification criteria for SRC and improve systematic research in this condition.

The SCTC SRC-WG that consists of international experts from rheumatology, nephrology and pathology was created in November 2015. A scoping review to generate evidence-based items to define SRC was performed during 2016, presented to the SCTC SRC WG in Washington, DC, in November 2016, and published in February 2017<sup>53</sup>. We identified 415 papers that met inclusion criteria. Forty original definitions of SRC were identified from 36 studies, 9 reviews and 2 editorials. There was significant heterogeneity in definitions. In May-October 2017, we conducted



a 3-round online Delphi exercise to develop initial consensus on a core set of items to define SRC. A survey using the items identified by the scoping review was developed. An international, multidisciplinary panel of experts from the SCTC, European Scleroderma Trials and Research Group (EUSTAR), the Canadian Scleroderma Research Group (CSRG), and the Australian Scleroderma Interest Group (ASIG) were invited to participate. A Delphi exercise was performed in 3 rounds. In Round 1, participants were asked to identify omissions and clarify ambiguities. The survey was modified accordingly. In Round 2, participants were asked to rate the scientific validity and feasibility of the items using Likert-type scales ranging from 1-9 (1= very invalid/unfeasible, 9 = very valid/feasible), and to provide comments. In Round 3, participants reviewed the results and were asked to provide final ratings. Consensus was defined as items rated highly valid and feasible (both median scores  $\geq 7$ ) in Round 3, and for which there was no disagreement, calculated using the RAND/UCLA Appropriateness Method formula<sup>54</sup>. Ninety-nine experts from 17 countries participated in the Delphi exercise. Of the 31 items in the survey, consensus was achieved on items pertaining to hypertension, kidney dysfunction, proteinuria and hemolysis. Consensus was not achieved on items pertaining to hematuria, thrombocytopenia, encephalopathy, retinopathy, hyper-reninemia, cardiac dysfunction and histopathology.

In November 2017, a nominal group discussion was held in San Diego, CA, to achieve final consensus on the core set. Final consensus was achieved on items for blood pressure, acute kidney injury, microangiopathic hemolytic anemia and thrombocytopenia, target organ dysfunction (cardiac dysfunction, retinopathy and encephalopathy) and histopathology.

Two additional components of this research project are now in the planning phases. First, modeled on the *International Scleroderma Renal Crisis Survey (ISRCS)*,<sup>52</sup> *ISRCS II* will be developed and launched to collect a new inception SRC cohort to validate the consensus criteria using data-driven

methods. Second, a forced choice study using multi-criteria decision analysis methods<sup>55</sup>, will be performed with the experts who participated in the nominal group discussion to assign weights to the items in the criteria.

This project will generate the first validated classification criteria for SRC. These criteria are expected to become the international standard and will be used in future randomized trials and epidemiologic research of SSc.

#### 10. **Skin WG.** PI: authors JG, PM, DK

Skin involvement in SSc is the most pathognomonic feature and an important manifestation of disease and a marker of severity<sup>56,57</sup>, which makes its assessment a key outcome in clinical research in SSc. Skin involvement is routinely quantified using the 17-site modified Rodnan skin score (mRSS) which assesses global dermal thickness through clinical palpation of 17 body areas scored using a 4-point ordinal scale. The mRSS has high feasibility, validity (face, content, construct, and criterion), reliability, and sensitivity to change<sup>58</sup>. The goal of this SCTC WG is to explore ways to improve the assessment of skin disease in SSc.

Although mRSS has excellent intra-rater and inter-rater reliabilities<sup>59,60</sup> individual examiners approach the mRSS in different ways in clinical practice. Commonly-used techniques for a given area of the body include choosing a maximum score, a representative area, or a global average. If the examiner is consistent with his or her approach to scoring each time, the mRSS will be valid in the course of a trial. However, it is possible that maximizing the score may lead to decreased sensitivity to change of the mRSS. This WG plans to explore this controversy.

It has been observed that certain areas of the body are more sensitive to change than others. Kaldas, et al showed that hands, forearms and chest were more sensitive to change compared with other

body sites in two human recombinant relaxin and oral bovine collagen clinical trials<sup>61</sup>. Fernandez, et al showed a lower propensity for change of the fingers over the course of 3 single-center trials<sup>62</sup>. These observations lead to the question of whether decreasing the number of body sites by exclusion of relatively static areas would further increase the sensitivity to change over time or reliability of the total MRSS. Our goal is to look at these questions in the context of studies that show more significant change as well as over a longer duration.

Further goals of this group will include investigation of complementary methods of assessing skin disease that can be studied as secondary outcomes in clinical trials. Ideas include percentage change mRSS, percentage of body involvement, and possibly use of skin biopsies, ultrasound, or durometry depending on investigator interest. Importantly, the WG seeks to align its agenda with the SCTC's efforts to standardize skin scoring and advance the science of clinical trials in SSc.

#### **11. Lung Disease WG.** PI: authors EB, SN

Interstitial lung disease (ILD) is the primary cause of death in SSc<sup>63</sup>. Although there have been many trials for the treatment of SSc-ILD, inclusion criteria have varied widely across studies and it remains unclear which patients to enroll to maximize the likelihood of achieving the predefined primary endpoints.

The aim of this WG is to harmonize inclusion criteria for clinical trials of SSc-ILD. We have reviewed the inclusion and exclusion criteria for 9 completed and ongoing SSc-ILD clinical trials since the year 2000<sup>64-74</sup>. While age at time of enrollment and SSc classification criteria were fairly consistent across studies, there was considerable variability with respect to disease duration, pulmonary function test (PFT) cut points, high resolution computed tomography of the chest (HRCT) characteristics, and acceptable background therapies. While some inclusion and

exclusion criteria will need to be specific to the particular drug being investigated, developing “optimal inclusion criteria” may ultimately help improve outcomes of SSc-ILD clinical trials.

At the inaugural meeting of the SCTC Lung Disease WG in 2017, an initial research agenda was defined as determining how best to define progression of SSc-ILD and whether SSc-ILD progresses in patients who have had SSc for  $\geq 7$  years. We will perform a nominal group technique and Delphi exercise to develop consensus among SSc experts. We will then apply the core set of inclusion and exclusion criteria to clinical trial data and observational cohort data to validate their performance. Using well-established SSc cohorts throughout the world and applying the definition of progressive SSc-ILD that we develop, we will subsequently determine whether patients with  $\geq 7$  years of disease have progression of their ILD.

## **Conclusions**

The SCTC WGs are one aspect of an organization tasked with improving the efficacy of clinical trials. This interim report summarizes the work of the SCTC WGs to date.

The group has benefited greatly from the input and effort of the SCTC members who have attended meetings over many years. Members generously contributed their time, effort and wide-ranging expertise on subjects as diverse as the disease that we are studying. Members' involvement has ensured that the WGs reports will reflect a wide range of perspectives and skills. Leaders of the groups are grateful for the tireless input of all those who have been involved in these many exercises.

## References:

1. Avouac J, Clements PJ, Khanna D, Furst DE, Allanore Y. Articular involvement in systemic sclerosis. *Rheumatology* 2012;51:1347-56.
2. Baron M, Lee P, Keystone EC. The articular manifestations of progressive systemic sclerosis (scleroderma). *Ann Rheum Dis* 1982;41:147-52.
3. Avouac J, Walker U, Tyndall A, et al. Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. *The Journal of rheumatology* 2010;37:1488-501.
4. Steen VD, Medsger TA, Jr. The palpable tendon friction rub: an important physical examination finding in patients with systemic sclerosis. *Arthritis and rheumatism* 1997;40:1146-51.
5. Avouac J, Walker UA, Hachulla E, et al. Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study. *Annals of the rheumatic diseases* 2016;75:103-9.
6. Clements PJ, Allanore Y, Khanna D, Singh M, Furst DE. Arthritis in systemic sclerosis: systematic review of the literature and suggestions for the performance of future clinical trials in systemic sclerosis arthritis. *Seminars in arthritis and rheumatism* 2012;41:801-14.
7. Tay T, Ferdowsi N, Baron M, et al. Measures of disease status in systemic sclerosis: A systematic review. *Semin Arthritis Rheum* 2017;46:473-87.
8. Valentini G, Della Rossa A, Bombardieri S, et al. European multicentre study to define disease activity criteria for systemic sclerosis.\* II. Identification of disease activity variables and development of preliminary activity indexes. *Ann Rheum Dis* 2001;60:592-8.
9. Valentini G, Iudici M, Walker UA, et al. The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. *Ann Rheum Dis* 2017;76:270-6.
10. Hao Y, Hudson M, Baron M, et al. Early Mortality in a Multinational Systemic Sclerosis Inception Cohort. *Arthritis & Rheumatology* 2017;69:1067-77.
11. Tugwell P, Boers M, Brooks P, Simon L, Strand V, Idzerda L. OMERACT: an international initiative to improve outcome measurement in rheumatology. *Trials* 2007;8:38.
12. Medsger TA, Jr., Silman AJ, Steen VD, et al. A disease severity scale for systemic sclerosis: development and testing. *Journal of Rheumatology* 1999;26:2159-67.
13. Steen V, Medsger TA. Severe Organ Involvement in Systemic Sclerosis with Diffuse Scleroderma. *Arthritis & Rheumatism* 2000;43:2437-44.
14. D'Angelo W, Fries JF, Masi AT, Shulman LE. Pathologic Observations in Systemic Sclerosis (Scleroderma) A Study of Fifty-Eight Autopsy Cases and Fifty-Eight Matched Controls. *American Journal of Medicine* 1969;46:428-40.
15. Bulkley BH, Ridolfi RL, Salyer WR, M. HG. Myocardial Lesions of Progressive Systemic Sclerosis A Cause of Cardiac Dysfunction. *Circulation* 1976;53:483-90.
16. Allanore Y, Meune C. Primary myocardial involvement in systemic sclerosis: evidence for a microvascular origin. *Clin Exp Rheumatol* 2010;2010:S48-S53.
17. Mavrogeni SI, Schwitter J, Gargani L, et al. Cardiovascular magnetic resonance in systemic sclerosis: "Pearls and pitfalls". *Seminars in Arthritis and Rheumatism* 2017;47:79-85.

18. Allanore Y, Meune C. N-terminal pro brain natriuretic peptide: the new cornerstone of cardiovascular assessment in systemic sclerosis. *Clinical & Experimental Rheumatology* 2009;27:59-63.
19. Avouac J, Meune C, Chenevier-Gobeaux C, et al. Cardiac Biomarkers in Systemic Sclerosis: Contribution of High-Sensitivity Cardiac Troponin in Addition to N-Terminal Pro-Brain Natriuretic Peptide. *Arthritis Care & Research* 2015;67:1022-30.
20. Barsotti S, Stagnaro C, d'Ascanio A, et al. High sensitivity troponin might be a marker of subclinical scleroderma heart involvement: a preliminary study. *Journal of Scleroderma and Related Disorders* 2017;2:183-7.
21. Herrick AL, Ennis H, Bhushan M, Silman AJ, Baildam EM. Incidence of childhood linear scleroderma and systemic sclerosis in the UK and Ireland. *Arthritis Care Res (Hoboken)* 2010;62:213-8.
22. La Torre F, Martini G, Russo R, et al. A preliminary disease severity score for juvenile systemic sclerosis. *Arthritis Rheum* 2012;64:4143-50.
23. Khanna D, Berrocal VJ, Giannini EH, et al. The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. *Arthritis & rheumatology (Hoboken, NJ)* 2016;68:299-311.
24. Medsger TA, Silman AJ, Steen VD, et al. Development of a severity score for systemic sclerosis. *Arthritis Rheum* 1995;37 Suppl:S 260.
25. Stefanska AM, Distlerova D, Musaus J, et al. Extrapolation in the development of paediatric medicines: examples from approvals for biological treatments for paediatric chronic immune-mediated inflammatory diseases. *Arch Dis Child* 2017;102:952-7.
26. Ruperto N, Brunner HI, Lovell DJ, Martini A, Paediatric Rheumatology International Trials O, the Pediatric Rheumatology Collaborative Study G. Extrapolation or controlled trials in paediatrics: the current dilemma. *Arch Dis Child* 2017;102:949-51.
27. Khanna D, Nagaraja V, Gladue H, Chey W, Pimentel M, Frech T. Measuring response in the gastrointestinal tract in systemic sclerosis. *Curr Opin Rheumatol* 2013;25:700-6.
28. Nagaraja V, Hays RD, Khanna PP, et al. Construct validity of the Patient-Reported Outcomes Measurement Information System gastrointestinal symptom scales in systemic sclerosis. *Arthritis Care Res (Hoboken)* 2014;66:1725-30.
29. Khanna D, Lovell DJ, Giannini E, et al. Development of a provisional core set of response measures for clinical trials of systemic sclerosis. *Ann Rheum Dis* 2008;67:703-9.
30. Wigley FM, Korn JH, Csuka ME, et al. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. *Arthritis Rheum* 1998;41:670-7.
31. Pauling JD, Frech TM, Domsic RT, Hudson M. Patient participation in patient-reported outcome instrument development in systemic sclerosis. *Clinical and Experimental Rheumatology* 2017;35:S184-S92.
32. Pauling JD, Shipley JA, Hart DJ, McGrogan A, McHugh NJ. Use of Laser Speckle Contrast Imaging to Assess Digital Microvascular Function in Primary Raynaud Phenomenon and Systemic Sclerosis: A Comparison Using the Raynaud Condition Score Diary. *J Rheumatol* 2015;42:1163-8.
33. Wilkinson JD, Leggett SA, Marjanovic EJ, et al. A multicentre study of validity and reliability of responses to hand cold challenge as measured by laser speckle contrast imaging and thermography: outcome measures for systemic sclerosis-related Raynaud's phenomenon. *Arthritis Rheumatol* 2018;ePublished ahead of print.

34. Gladue H, Maranian P, Paulus HE, Khanna D. Evaluation of test characteristics for outcome measures used in Raynaud's phenomenon clinical trials. *Arthritis Care Res (Hoboken)* 2013;65:630-6.
35. Pauling J, Frech TM, Hughes M, et al. Attitudes Toward Patient-Reported Outcome Instruments for the Assessment of Raynaud's Phenomenon in Systemic Sclerosis. *Arthritis & Rheumatology* 2016;68.
36. Pauling JD, Saketkoo, L.A., Matucci Cerinic, M., Ingegnoli, F., Khanna, D. The patient experience of Raynaud's phenomenon in systemic sclerosis. *Rheumatology* 2018;ePublished ahead of print.
37. Pauling JD, Domsic RT, Saketkoo LA, et al. A multi-national qualitative research study exploring the patient experience of Raynaud's phenomenon in systemic sclerosis. *Arthritis Care Res (Hoboken)* 2017;ePublished ahead of print.
38. Pauling JD, Saketkoo LA, Domsic RT. Patient perceptions of the Raynaud's Condition Score diary provide insight into its performance in clinical trials of Raynaud's phenomenon. *Arthritis Rheumatol* 2018;(ePublished ahead of print).
39. Herrick AL, van den Hoogen F, Gabrielli A, et al. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. *Arthritis Rheum* 2011;63:775-82.
40. Denton CP, Hachulla E, Riemekasten G, et al. Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study. *Arthritis Rheumatol* 2017;69:2370-9.
41. Gutierrez A, Jr., Wetter DA. Calcinosis cutis in autoimmune connective tissue diseases. *Dermatologic therapy* 2012;25:195-206.
42. Valenzuela A, Baron M, Herrick AL, et al. Calcinosis is associated with digital ulcers and osteoporosis in patients with systemic sclerosis: A Scleroderma Clinical Trials Consortium study. *Semin Arthritis Rheum* 2016;46:344-9.
43. Herrick AL, Gallas A. Systemic sclerosis-related calcinosis. *Journal of Scleroderma and Related Disorders* 2016;1:194-203.
44. Avouac J, Mogavero G, Guerini H, et al. Predictive factors of hand radiographic lesions in systemic sclerosis: a prospective study. *Annals of the rheumatic diseases* 2011;70:630-3.
45. Koutaissoff S, Vanthuyne M, Smith V, et al. Hand radiological damage in systemic sclerosis: comparison with a control group and clinical and functional correlations. *Seminars in arthritis and rheumatism* 2011;40:455-60.
46. Morardet L, Avouac J, Sasmour M, et al. Late nailfold videocapillaroscopy patterns associated with hand calcinosis and acro-osteolysis in systemic sclerosis. *Arthritis Care Res (Hoboken)* 2015.
47. Johnstone EM, Hutchinson CE, Vail A, Chevance A, Herrick AL. Acro-osteolysis in systemic sclerosis is associated with digital ischaemia and severe calcinosis. *Rheumatology* 2012;51:2234-8.
48. Gauhar R, Wilkinson J, Harris J, Manning J, Herrick AL. Calcinosis preferentially affects the thumb compared to other fingers in patients with systemic sclerosis. *Scandinavian journal of rheumatology* 2016:1-4.
49. Chung L, Valenzuela A, Fiorentino D, et al. Validation of a Novel Radiographic Scoring System for Calcinosis Affecting the Hands of Patients with Systemic Sclerosis. *Arthritis Care Res (Hoboken)* 2014.

50. Christensen Md A, Khaliq Md S, Cenac Md S, et al. SYSTEMIC SCLEROSIS RELATED CALCINOSIS: PATIENTS PROVIDE WHAT SPECIALISTS WANT TO LEARN. *The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society* 2015;167:158-9.
51. Steen VD, Mayes MD, Merkel PA. Assessment of kidney involvement. *Clin Exp Rheumatol* 2003;21:S29-31.
52. Hudson M, Baron M, Tatibouet S, Furst DE, Khanna D, International Scleroderma Renal Crisis Study I. Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis Survey. *Semin Arthritis Rheum* 2014;43:666-72.
53. Hoa S, Stern EP, Denton CP, Hudson M, Scleroderma Clinical Trials Consortium Scleroderma Renal Crisis Working Group Investigators of the Scleroderma Clinical Trials Consortium Scleroderma Renal Crisis Working G. Towards developing criteria for scleroderma renal crisis: A scoping review. *Autoimmun Rev* 2017;16:407-15.
54. Fitch K, Bernstein S, Aguilar M, et al. *The RAND/UCLA Appropriateness Method User's Manual*. Santa Monica, CA: Rand; 2001.
55. Johnson SR, Naden RP, Fransen J, et al. Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. *J Clin Epidemiol* 2014;67:706-14.
56. Steen V, Medsger TA, Jr. Improvement in skin thickening in systemic sclerosis associated with improved survival. *Arthritis and rheumatism* 2001;44:2828-35.
57. Clements PJ, Hurwitz EL, Wong WK, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. *Arthritis and rheumatism* 2000;43:2445-54.
58. Khanna D, Furst DE, Clements PJ, et al. Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. *Journal of scleroderma and related disorders* 2017;2:11-8.
59. Clements P, Lachenbruch P, Siebold J, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. *The Journal of rheumatology* 1995;22:1281-5.
60. Gordon JK, Girish G, Berrocal VJ, et al. Reliability and Validity of the Tender and Swollen Joint Counts and the Modified Rodnan Skin Score in Early Diffuse Cutaneous Systemic Sclerosis: Analysis from the Prospective Registry of Early Systemic Sclerosis Cohort. *J Rheumatol* 2017;44:791-4.
61. Kaldas M, Khanna PP, Furst DE, et al. Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis--assessment of individual body sites in two large randomized controlled trials. *Rheumatology* 2009;48:1143-6.
62. Fernandez A, Spiera R, Szymonifka J, Gordon J. Improving Sensitivity to Change of the Modified Rodnan Skin Score over Time. *Arthritis & rheumatology (Hoboken, NJ)* 2017;69.
63. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. *Ann Rheum Dis* 2007;66:940-4.
64. Kuwana M, Kaburaki J, Arnett FC, Howard RF, Medsger TA, Jr., Wright TM. Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody. *Arthritis and rheumatism* 1999;42:465-74.
65. Jimenez S, Gershwin M. Animal models of systemic sclerosis. In: Clements P, Furst D, eds. *Systemic Sclerosis*. 1st ed. Baltimore: Williams & Wilkins; 1996:251-73.



66. Jacobsen S, Ullman S, Shen GQ, Wiik A, Halberg P. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. *The Journal of rheumatology* 2001;28:2454-9.
67. Hesselstrand R, Scheja A, Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. *Annals of the rheumatic diseases* 1998;57:682-6.
68. Jacobsen S, Halberg P, Ullman S. Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma). *British journal of rheumatology* 1998;37:750-5.
69. Distler O, Brown KK, Distler JHW, et al. Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS). *Clin Exp Rheumatol* 2017;35 Suppl 106:75-81.
70. Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. *Arthritis and rheumatism* 2006;54:3962-70.
71. Khanna D, Albera C, Fischer A, et al. An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial. *J Rheumatol* 2016;43:1672-9.
72. Martyanov V, Kim GJ, Hayes W, et al. Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease. *PLoS One* 2017;12:e0187580.
73. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. *N Engl J Med* 2006;354:2655-66.
74. Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. *Lancet Respir Med* 2016;4:708-19.